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INTRODUCTION
Brain metastasis from breast cancer is less common than 
metastasis to the bone, lung, and liver. However, the prognosis 
of brain metastasis is very poor, with a median survival time 
ranging between 5.4 and 13 months. Additionally, it is usually 
discovered at a later stage during the systemic progression of 
breast cancer [1,2]. While brain metastasis is generally ob-
served in 10% to 20% of patients with metastatic breast cancers 
(MBC), autopsy series have revealed that it is, in fact, present 
in > 34% of patients [1,3]. Current therapies for brain metasta-
sis include whole brain radiotherapy (WBRT), surgery, stereo-
tactic radiation therapy (SRT), corticosteroids, and systemic 
chemotherapy. WBRT is considered the standard treatment 
for metastatic brain tumors (MBT); the role of chemotherapy 
is still controversial owing to the difficulties associated with 
passage through the blood-brain barrier (BBB) [1,2].
Eribulin is a microtubule dynamic inhibitor synthesized 
from halichondrin B, a natural marine product [4]. Halichon-
drin B binds to tubulin in the vinca domain, thereby inhibit-
ing tubulin polymerization. However, unlike other tubulin 
polymerization inhibitors, halichondrin B does not function 
by inhibiting tubulin growth or by shortening the microtubule 
[5,6]. Eribulin is currently acknowledged as a new line of 
therapy for MBC [7]. In a phase III study (eribulin monother-
apy versus treatment of physician’s choice in patients with 
MBC [EMBRACE]), eribulin treatment improved overall sur-
vival in patients with heavily pretreated MBC, but these stud-
ies included few patients with brain metastases [8]. Therefore, 
it is crucial to evaluate the effectiveness and safety of eribulin 
in the treatment of patients with breast cancer with brain me-
tastasis.
Herein, we report two cases of breast cancer with brain me-
tastasis that were treated with eribulin mesylate combined 
with local treatment for MBT. 
CASE REPORTS
Case 1
MBT were found during first-line palliative chemotherapy 
(docetaxel plus capecitabine) in a 43-year-old woman with 
breast cancer with metastasis to the lung and the mediastinal 
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The prognosis associated with brain metastasis arising from 
breast cancer is very poor. Eribulin is a microtubule dynamic in-
hibitor synthesized from halichondrin B, a natural marine prod-
uct. In a phase III study (EMBRACE), eribulin improved overall 
survival in patients with heavily pretreated metastatic breast can-
cers. However, these studies included few patients with brain 
metastases. Metastatic brain tumors (MBT) were detected dur-
ing first-line palliative chemotherapy in a 43-year-old woman 
with breast cancer metastasis to the lung and mediastinal 
nodes; the genetic subtype was luminal B-like human epidermal 
growth factor receptor 2 (HER2)-negative. Whole brain radio-
therapy (WBRT) followed by eribulin treatment continuously de-
creased the size, and induced regression, of the MBT with sys-
temic disease stability for 12 months. Another 48-year-old wom-
an with metastatic breast cancer (HER2+ subtype) presented 
with MBT. Following surgical resection of the tumor, eribulin with 
concurrent WBRT showed regression of the MBT without sys-
temic progression for 18 months. 
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nodes, in Inje University Busan Paik Hospital in June 2013. The 
patient complained of headache and tinnitus but there were no 
neurologic symptoms. Magnetic resonance imaging (MRI) of 
her brain showed two metastatic lesions with edema at the ce-
rebrum; the larger lesion measured 2.7× 2.1 cm (Figure 1A). 
Five years earlier, in July 2008, the patient had undergone a 
left modified radical mastectomy for invasive ductal carcino-
ma. The pathologic stage of the disease was T3N3M0 and the 
histologic grade was low. The genetic subtype was luminal B-
like human epidermal growth factor receptor 2 (HER2)-nega-
tive, which was positive for estrogen receptor (ER) and pro-
gesterone receptor (PR), negative for HER2, and the Ki-67 la-
beling index > 14%. The patient received adjuvant chemo-
therapy with doxorubicin and cyclophosphamide followed by 
paclitaxel (doxorubicin 60 mg/m2 and cyclophosphamide 600 
mg/m2, every 3 weeks, intravenously for four cycles; followed 
by paclitaxel 175 mg/m2, every 3 weeks, intravenously for four 
cycles). Following the chemotherapy treatment, she received 
radiation therapy and tamoxifen. 
Four years after the surgery, in May 2012, positron emission 
tomography (PET) revealed metastases in the patient’s right 
lung, and in her paratracheal, subcarinal, and right supracla-
vicular lymph nodes, although she showed no symptoms or 
signs of either local or distant metastatic recurrence. A needle 
biopsy confirmed the presence of metastatic lesions from 
breast cancer in the right supraclavicular lymph node. The ge-
netic subtype of the metastatic node was luminal B-like 
HER2-negative (ER-positive, PR-negative, HER2-negative, 
and Ki-67 labeling index > 14%). Based on the first-line palli-
ative chemotherapy, the patient received docetaxel (75 mg/m2, 
every 3 weeks, intravenously) plus capecitabine (1,250 mg/m2 
bis in die, per os [p.o.], on days 1–14, with a 1-week withdraw-
al period, every 3 weeks) for 15 cycles. 
The MBT were detected during the docetaxel plus capecitabine 
chemotherapy in June 2013 (Figure 1A). The patient underwent 
γ-knife SRT and received CMF (cyclophosphamide 100 mg/
m2 p.o., on days 1–14, methotrexate 40 mg/m2 intravenously 
on days 1 and 8, and 5-fluorouracil 600 mg/m2 intravenously 
on days 1 and 8, every 4 weeks) for four cycles as second-line 
palliative chemotherapy. The 4-month follow-up brain MRI 
showed that the metastatic lesion had decreased in size from 
2.7 to 2.5 cm (Figure 1B), but the PET-computed tomography 
(CT) image showed increased glucose uptake and size in the 
metastatic lymph nodes of the mediastinum, indicating aggra-
vation. 
The patient received WBRT (total 3,000 cGy: 300 cGy/day 
for 10 days). She then received eribulin single therapy (1.4 g/m2 
on days 1 and 8, intravenously, every 3 weeks) 4 days later as 
third-line palliative chemotherapy in November 2013. At the 
3-month follow-up appointment, after the fourth cycle of 
eribulin, the MBT had further decreased in size; the heteroge-
neous enhancing lesion decreased from 2.5 to 1.7 cm. Add-
itionally, the oval-shaped cystic lesion had decreased from 1.5 
to 0.8 cm (Figure 2A). After the sixth cycle of eribulin treat-
ment, the patient discontinued use owing to financial reasons; 
the eribulin therapy was restarted 3 months later. At the 
8-month follow-up examination in July 2014, after the eighth 
cycle of eribulin treatment, the MBT showed regression with 
systematically stable disease (Figure 2B). The patient was still 
receiving eribulin and there were no severe hematologic or 
non-hematologic adverse events reported during or after the 
chemotherapy. At the 10-month follow-up examination in 
September 2014, following the tenth cycle of eribulin treat-
ment, a PET-CT scan showed that the mediastinal nodes had 
increased in size and that glucose metabolism in these nodes 
had also increased. The MBT progressed systemically 12 
months after eribulin single therapy in November 2014. 
As the patient had the luminal B breast cancer subtype, and 
Figure 1. Magnetic resonance imaging in case 1. (A) A heterogeneous enhancing brain parenchymal mass with hemorrhagic component (2.7×2.1 
cm) and a rim enhancing cystic mass (1.5×1.2 cm) were identified on right frontoparietal region of the cerebrum in June 2013. (B) Response of meta­
static brain tumors to gamma knife stereotactic radiation therapy in October 2013. The metastatic le sion had decreased in size from 2.7 to 2.5 cm. A 
cystic lesion in anterior portion showed no gross interval change (1.5×1.2 cm)
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she was postmenopausal, we initiated treatment with an aro-
matase inhibitor (letrozole) in December 2014. In July 2015, 
we changed the regimen to everolimus plus exemestane due 
to systemic progression. The patient is still alive, without any 
neurologic symptoms, more than 24 months following the 
MBT diagnosis.
Case 2
In May 2012, a 47-year-old woman visited the Breast Cancer 
Center of Gangnam Severance Hospital for evaluation of an ul-
cerofungating mass involving her right whole breast. She was 
diagnosed with stage IV invasive ductal carcinoma (cT4N3M1), 
which had metastasized to distant organs including the liver 
and bone. Pathological examination via immunohistochemis-
try showed that the tumor was ER- and PR-negative, and 
HER2-positive. Primary systemic chemotherapy, consisting of 
six cycles of docetaxel (75 mg/m2, every 3 weeks, intravenous-
ly) and doxorubicin (50 mg/m2, every 3 weeks, intravenously) 
was administered from May 2012 to August 2012. Salvage 
mastectomy for wound management was performed in Sep-
tember 2012. Two months after completion of the first-line 
treatment, a follow-up liver CT showed progression of the he-
patic metastasis with increased tumor number and size. As a 
second-line systemic treatment, paclitaxel (75 mg/m2, every 3 
weeks, intravenously) and trastuzumab (8 mg/kg loading dose 
and 6 mg/kg, every 3 weeks, intravenously) were adminis-
tered. In May 2013, a liver CT revealed that the metastatic le-
sions in the liver had progressed despite the six cycles of pacli-
taxel and trastuzumab. The patient was treated with lapatinib 
(1,250 mg, daily, p.o.) and capecitabine (2,000 mg/m2, on days 
1–14, every 3 weeks, p.o.) as third-line chemotherapy. A par-
tial response was achieved. 
Despite this partial response, brain metastasis developed af-
ter 20 cycles of lapatinib and capecitabine. On July 20, 2014, 
the patient visited the emergency department with right-sided 
weakness. A brain MRI identified a 2.5-cm metastatic lesion 
on her left frontal-parietal lobe (Figure 3A). Craniotomy and 
surgical resection of the tumor was successfully performed on 
July 21, 2014. At the time of the brain metastasis, a newly de-
veloped lesion was found in the S8 area of the liver on CT per-
formed on July 29, 2014. After tumor removal, systemic thera-
py with eribulin (1.4 g/m2, on days 1 and 8, every 3 weeks, in-
travenously) was started in August 2014. For further local 
treatment of the brain metastasis, the patient received WBRT 
(total 3,000 cGy: 250 cGy/day for 12 days) with a boost dose to 
the tumor bed (total 3,600 cGy: 300 cGy/day for 12 days). Dur-
ing the treatment period with eribulin, local wound dehiscence 
developed at the site of craniotomy in the scalp. To manage 
this, a local skin flap surgery was performed, and the eribulin 
treatment was temporally halted for 4 weeks. As of December 
2015, the patient was on her 23rd cycle of eribulin, without tu-
mor recurrence or progression in the brain or liver. Her last 
follow-up studies, including brain MRI and liver CT, carried 
out on November 20, 2015 revealed stable disease (Figure 3B). 
Figure 2. Magnetic resonance imaging after whole brain radiotherapy followed by eribulin in case 1. (A) The posterior heterogeneous enhancing lesion 
and anterior oval shaped cystic lesion had continuously decreased respectively (2.5 to 1.7 cm and 1.5 to 0.8 cm) in January 2014. (B) The het­
erogeneous enhancing lesion and oval shaped cystic mass had regressed respectively (1.7 to 1.2 cm and 0.8 to 0.6 cm) in July 2014. 
A B
Figure 3. Magnetic resonance imaging after surgery followed by eribulin 
with concurrent whole brain radiotherapy in case 2. (A) A 2.5 cm meta­
static lesion with edema was iden tified on her left frontal­parietal lobe in 
July 2014. (B) No tumor recurrence showed in her brain after treatment 
in November 2015.
A B
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DISCUSSION
The clinical regression, without symptoms, of MBT from 
breast cancer was sustained for 24 and 18 months in case 1 
and case 2, respectively, using multimodality therapies that in-
cluded surgery, SRT, WBRT, chemotherapy, and endocrine 
therapy. WBRT followed by eribulin induced a continuous 
decrease in the size of the MBT with systemic disease stability 
for 12 months in case 1. Surgery followed by eribulin with 
concurrent WBRT inhibited systemic progression for 18 
months in case 2. 
In order to effectively treat MBT, a chemotherapeutic agent 
should induce effective cytotoxicity in the tumor cells. It 
should be able to reach adequate concentrations, maintain 
this concentration in the tumor’s extracellular space, and cross 
the BBB while evading active efflux mechanisms [2]. Com-
pared with that of primary brain tumors, the BBB of MBT 
tends to be relatively permeable [9]. In addition, the expres-
sion of P-glycoprotein (P-gp), which is associated with perme-
ability of the BBB, is decreased in MBT [10]. Furthermore, the 
permeability of the BBB can be increased by WBRT [11,12]. 
In line with our experience, a previous case report showed 
that eribulin therapy may be beneficial in the treatment of 
MBT arising from breast cancer [13]. In a patient with pro-
gression of brain and liver metastasis after WBRT followed by 
lapatinib and capecitabine treatment, eribulin achieved a sig-
nificant response in the MBT 1 month later and this effect 
lasted for 4 months. 
The following hypotheses could explain the mechanism of 
the therapeutic effect of eribulin on MBT in our cases: first, 
eribulin was efficacious against the systemic disease; second, 
WBRT may have facilitated the passage of eribulin across the 
BBB by decreasing the function of P-gp; third, the antiangio-
genic action of eribulin could have increased the transmission 
of eribulin itself. A new mode of action for eribulin that in-
volves remodeling of the tumor vasculature through a novel 
antivascular activity has already been reported [14]. 
Eribulin may offer a clinical benefit in the treatment of 
MBT arising from breast cancer. WBRT followed by eribulin, 
or eribulin with concurrent WBRT may represent an effective 
treatment option for breast cancer patients with brain metas-
tasis. Future studies are warranted to evaluate the precise effect 
of eribulin and its mechanism of action on brain metastasis.
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